Your browser is no longer supported. Please, upgrade your browser.
Settings
OGEN Oragenics, Inc. daily Stock Chart
OGEN [NYSE]
Oragenics, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own1.10% Shs Outstand31.28M Perf Week-13.64%
Market Cap35.66M Forward P/E- EPS next Y- Insider Trans96.58% Shs Float27.13M Perf Month184.29%
Income-7.90M PEG- EPS next Q- Inst Own11.20% Short Float5.12% Perf Quarter72.44%
Sales- P/S- EPS this Y28.30% Inst Trans30.80% Short Ratio0.21 Perf Half Y-30.19%
Book/sh-0.41 P/B- EPS next Y- ROA-137.60% Target Price2.00 Perf Year-71.96%
Cash/sh0.12 P/C9.14 EPS next 5Y- ROE711.00% 52W Range0.38 - 4.71 Perf YTD-51.47%
Dividend- P/FCF- EPS past 5Y21.70% ROI- 52W High-75.81% Beta0.53
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low200.00% ATR0.39
Employees12 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)50.68 Volatility29.39% 36.63%
OptionableNo Debt/Eq- EPS Q/Q-52.70% Profit Margin- Rel Volume0.36 Prev Close1.11
ShortableYes LT Debt/Eq- EarningsNov 12 AMC Payout- Avg Volume6.57M Price1.14
Recom1.00 SMA20-4.14% SMA5053.22% SMA200-18.28% Volume2,370,288 Change2.70%
Oct-12-18 08:00AM  Today's Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals ACCESSWIRE -6.72%
Oct-10-18 10:30AM  This Weeks Biotech and Cannabis Stocks to Watch ACCESSWIRE -21.21%
Oct-05-18 12:05PM  Should You Worry About The Oragenics Incs (NYSEMKT:OGEN) Shareholder Register? Simply Wall St.
Oct-04-18 10:30AM  These Stocks Are on The Brink of Breakouts ACCESSWIRE -13.71%
08:19AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Oct-02-18 10:30AM  Biotech Market is Rolling and These Companies Need to Be on Your Radar ACCESSWIRE +123.12%
Sep-25-18 07:45AM  Oragenics, Inc. to Present at Upcoming Conferences in October Business Wire -35.48%
Sep-24-18 08:00AM  Todays Research Reports on Stocks to Watch: Oragenics and Pfizer ACCESSWIRE +29.17%
07:20AM  Can Oragenics Inc (NYSEMKT:OGEN) Improve Your Portfolio Returns? Simply Wall St.
Sep-17-18 03:49PM  Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)? Simply Wall St.
09:13AM  Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018 Business Wire
Aug-17-18 01:30PM  OGEN: Positive DSMB Review for Phase 2 Trial of AG013 Zacks Small Cap Research
Aug-15-18 07:30AM  Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review Business Wire
Jul-27-18 07:55AM  Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks ACCESSWIRE
Jul-20-18 09:30AM  OGEN: Raises Net Proceeds of $12.3 Million in Underwritten Public Offering Zacks Small Cap Research -7.98%
Jul-17-18 04:15PM  Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Business Wire -9.24%
Jul-13-18 08:16AM  Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering Business Wire -34.43%
Jun-27-18 07:20AM  Free Technical Research on Nektar Therapeutics and Three More Biotech Equities ACCESSWIRE
Jun-20-18 09:30AM  Diamond Equity Research Initiates Coverage on Oragenics Inc. (NYSE:OGEN) with a Valuation of $3.50 Per Share GlobeNewswire +11.64%
Jun-13-18 08:30AM  Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections Business Wire
Jun-11-18 10:30AM  OGEN: Initiating Coverage of Oragenics, Inc.; Developing a Novel Class of Antibiotics and Treatment for Oral Mucositis Zacks Small Cap Research
Jun-05-18 12:26PM  Is Oragenics Incs (NYSEMKT:OGEN) CEO Paid At A Competitive Rate? Simply Wall St. +7.14%
May-31-18 08:20AM  Todays Research Reports on Stocks to Watch: Oragenics and Sigma Labs ACCESSWIRE -25.00%
May-30-18 07:30AM  Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire +66.67%
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-23-18 02:00PM  Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140 Business Wire +19.66%
Apr-20-18 07:38PM  Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)? Simply Wall St.
Apr-13-18 12:31PM  Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market? Simply Wall St.
Apr-06-18 02:25PM  Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering Business Wire
Mar-23-18 08:30PM  Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire
Mar-19-18 07:30AM  Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile Business Wire +9.45%
Mar-12-18 12:06PM  Did Oragenics Incs (NYSEMKT:OGEN) Earnings Growth Outperform The Industry? Simply Wall St. -11.49%
Mar-06-18 03:18PM  Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House ACCESSWIRE +9.60%
Feb-20-18 04:15PM  Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Business Wire
Jan-08-18 07:15AM  Oragenics, Inc. Announces Reverse Stock Split Business Wire -23.27%
Nov-28-17 09:36AM  Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry? Simply Wall St.
Nov-13-17 07:00AM  Oragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards Business Wire
Nov-09-17 07:00AM  Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity Business Wire
Oct-27-17 01:41PM  Oragenics Inc (OGEN): Time For A Financial Health Check Simply Wall St.
Sep-28-17 09:25AM  Is Oragenics Inc (OGEN) A Good Healthcare Bet? Simply Wall St.
Sep-06-17 06:49PM  Oragenics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Business Wire
Aug-31-17 07:30AM  Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire
Aug-14-17 07:32PM  Oragenics reports 2Q loss Associated Press +9.03%
Jul-26-17 07:45AM  Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement Business Wire
Jun-09-17 05:00PM  Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard Business Wire
Jun-06-17 06:47PM  Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference Business Wire
May-16-17 12:18PM  How these two Tampa Bay companies got the financing to grow their technology American City Business Journals +16.16%
May-11-17 12:38PM  CORRECTION FROM SOURCE: Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan Accesswire -5.95%
12:10PM  Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan Accesswire
07:45AM  Oragenics Announces $3.0 Million Preferred Stock Private Placement and $2.4 Million Loan Business Wire
Apr-18-17 01:12PM  Oragenics Provides First Quarter 2017 Update Business Wire
Mar-03-17 04:45PM  Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Business Wire
01:04PM  ORAGENICS INC Financials
Mar-01-17 05:10PM  Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results PR Newswire
Feb-27-17 04:11PM  ORAGENICS INC Files SEC form 10-K, Annual Report
Jan-31-17 05:17PM  ORAGENICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-04-17 07:45AM  Oragenics Shareholder Update Business Wire +9.16%
Dec-15-16 07:45AM  Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development Business Wire
Nov-23-16 10:16AM  Oragenics AG013 Drug Gets Fast Track Status (OGEN) Investopedia -11.25%
10:16AM  Oragenics AG013 Drug Gets Fast Track Status (OGEN) at Investopedia
08:18AM  Oragenics Jumps on Fast Track Status for Oral Mucositis Drug Zacks
Nov-22-16 05:59AM  Oragenics Practically Doubles on FDA Decision 24/7 Wall St.
Nov-21-16 03:29PM  U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis Business Wire +81.40%
09:01AM  ORAGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-14-16 05:45PM  ORAGENICS INC Files SEC form 10-Q, Quarterly Report
Sep-15-16 03:18PM  ORAGENICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-30-16 04:08PM  ORAGENICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
08:15AM  Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment Business Wire
Aug-26-16 02:42PM  Tampa biopharmas $30M capital raise could aid people with infections, cancer at bizjournals.com
Aug-23-16 08:44AM  ORAGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections Business Wire
Aug-15-16 06:24PM  Oragenics reports 2Q loss
04:10PM  ORAGENICS INC Files SEC form 10-Q, Quarterly Report
Aug-01-16 04:31PM  Oragenics Announces Receipt of Payment in Full under Promissory Note in Connection with Sale of Consumer Probiotic Business Business Wire
Jul-20-16 12:48PM  ETFs with exposure to Oragenics, Inc. : July 20, 2016
Jul-19-16 01:25PM  Tampa biopharma back on track with New York Stock Exchange at bizjournals.com
08:56AM  ORAGENICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra
08:30AM  Oragenics, Inc. Announces NYSE MKT Acceptance of its Plan of Compliance Business Wire
Jul-08-16 04:26PM  ORAGENICS INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and Exhibits
Jun-30-16 05:00PM  ORAGENICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
04:30PM  Oragenics Announces Closing of $4.667 Million Private Placement Business Wire
Jun-27-16 08:41AM  ORAGENICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dispositio
08:00AM  Oragenics Announces Completion of Sale of Consumer Probiotic Business Business Wire
Jun-23-16 08:25AM  ORAGENICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satis
08:00AM  Oragenics Announces Entry into Definitive Agreement to Sell Consumer Probiotic Business Business Wire
Jun-06-16 05:05PM  ORAGENICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:51PM  Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors Business Wire
12:13PM  Oragenics, Inc. :OGEN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-24-16 07:00AM  Stock exchange warnings pile up at Odyssey, other companies with Tampa ties at bizjournals.com
May-16-16 05:51PM  Oragenics reports 1Q loss
04:33PM  ORAGENICS INC Files SEC form 10-Q, Quarterly Report
May-13-16 05:32PM  ORAGENICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra
05:12PM  Oragenics, Inc. Announces Notification of Noncompliance with NYSE MKT Continued Listing Standards Business Wire
May-02-16 04:45PM  Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol Business Wire
Apr-05-16 11:48AM  Oragenics, Inc. :OGEN-US: Earnings Analysis: Q4, 2015 By the Numbers
10:39AM  Oragenics, Inc. :OGEN-US: Earnings Analysis: 2015 By the Numbers
Apr-01-16 05:00PM  Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Business Wire
Mar-30-16 04:38PM  ORAGENICS INC Files SEC form 10-K, Annual Report
Feb-19-16 08:15AM  Oragenics Receives New Patent for Improved Replacement Therapy for Dental Caries Business Wire
Dec-31-15 08:05AM  Tampa Bay's top-performing stock of 2015 may surprise you at bizjournals.com
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KOSKI FAMILY LP10% OwnerSep 18Buy0.4122,0009,009277,839Sep 18 04:07 PM
KOSKI FAMILY LP10% OwnerSep 17Buy0.42100,00042,000255,839Sep 18 04:07 PM
KOSKI FAMILY LP10% OwnerSep 14Buy0.4247,05019,718155,839Sep 18 04:07 PM